External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology ASOPRS 2023
Roche and Genentech

ASOPRS 2023

November 02 - November 03
San Francisco, USA
asoprsconf.memberclicks.net
Add to calendar
Share feedback
Share page
-
Medical Materials
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Nov 6 / Roche and Genentech
Inhibition of IL-6 Receptor Signaling with Satralizumab▼ in Thyroid Eye Disease: Phase 3 SatraGO-1 and SatraGO-2 Trial Design
Thyroid eye disease (TED) is a rare, autoimmune, inflammatory ocular disorder that is potentially sight-threatening, disfiguring, and debilitating. This presentation describes the rationale and design of the Phase 3 SatraGO-1 and SatraGO-2 trials evaluating the efficacy and safety of satralizumab▼, a humanized monoclonal antibody developed using antibody recycling technology to target the IL-6 receptor pathway, in participants with active and inactive TED.
Ophthalmology Thyroid eye disease ASOPRS-2023

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.